When "High Risk" Is Safe: FDA Stays on GAO List For 2011
This article was originally published in RPM Report
The Government Accountability Office isn’t ready to give FDA a clean bill of health, keeping the agency on its biennial list of “high risk” government programs for 2011-2012. That’s not flattering to the agency, but it should help FDA in the current climate of tight budgets.
You may also be interested in...
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.